PNMA2 and neoplasm: The MA2 Fc DLE mutant killed tumor cells through ADCC activity against MART1 peptide-pulsed A375 melanoma cells (Extended Data Fig. 6c) but spared off-target peptide-pulsed A375 cells (Fig. 5g), underscoring MA2’s peptide selectivity.